8-K: ModivCare Adjusts 2024 Guidance Amid Receivable Collection Delays, Eyes 2025 Growth

ModivCare has revised its 2024 Adjusted EBITDA guidance due to collection delays and strategic pricing adjustments, while projecting over 10% growth in 2025.

Summary

• ModivCare has updated its financial outlook, primarily due to delays in collecting approximately $60 million of its $159.3 million in NEMT contract receivables as of June 30, 2024.
• These delays are mainly attributed to Medicaid redeterminations and increased utilization under shared-risk contracts.
• The company has revised its 2024 Adjusted EBITDA guidance from $185-$195 million to $170-$180 million.
• This adjustment is also due to pricing accommodations made to retain and expand key customer relationships in the NEMT segment.
• ModivCare anticipates over 10% Adjusted EBITDA growth in 2025, based on the updated 2024 guidance.
• The company is in discussions with its bank group to seek near-term covenant relief under its revolving credit facility.
• ModivCare filed a Form S-3 shelf registration statement on September 12, 2024, to provide flexibility for raising capital over the next three years, though they do not plan to issue equity at this time.

Sentiment

Score: 4

Explanation: The document contains negative news regarding reduced guidance and collection delays, but also includes positive forward-looking statements about 2025 growth and the company's confidence in collecting receivables. The overall sentiment is cautiously negative.

Positives

• ModivCare is confident in collecting outstanding receivables from its MCO and state payor customers.
• The company expects to enter 2025 with aligned prepayment rates, anticipating the collection situation to stabilize.
• ModivCare projects over 10% Adjusted EBITDA growth in 2025.
• The company has engaged in collaborative and supportive discussions with its bank group regarding covenant relief.
• The Form S-3 shelf registration provides financial flexibility for the next three years.

Negatives

• ModivCare has experienced delays in collecting approximately $60 million in NEMT contract receivables.
• The company has lowered its 2024 Adjusted EBITDA guidance by $15 million at the midpoint.
• The delays in collections are primarily due to Medicaid redeterminations and increased utilization under shared-risk contracts.
• Pricing accommodations were made to strategically retain and expand key customer relationships, impacting the 2024 Adjusted EBITDA.

Risks

• There are risks associated with government or private insurance program funding reductions or limitations.
• The implementation of alternative payment models or the transition of Medicaid and Medicare beneficiaries to Managed Care Organizations could pose challenges.
• The company faces risks related to its ability to control reimbursement rates received for services.
• Delays in collection, or non-collection, of accounts receivable could impact financial performance.
• The company's existing debt agreements contain restrictions, financial covenants and cross-default provisions that limit its flexibility.
• There is a risk of not successfully executing on strategies in the face of competition.

Future Outlook

ModivCare anticipates over 10% Adjusted EBITDA growth in 2025, based on the updated 2024 guidance and expects to enter 2025 with aligned prepayment rates.

Management Comments

• Modivcare remains confident in collecting outstanding receivables from its managed care organizations (MCOs) and state payor customers.
• The company is focused on seeking near-term covenant relief under its revolving credit facility to address potential delays in contract receivable collections.

Industry Context

The announcement reflects challenges in the healthcare services sector related to Medicaid redeterminations and the impact on contract receivables, which is a common issue for companies operating in this space. The need for covenant relief and the filing of a shelf registration statement are indicative of the current financial pressures faced by some healthcare providers.

Comparison to Industry Standards

• The delay in collecting $60 million of receivables is significant and highlights potential issues with ModivCare's revenue cycle management compared to peers.
• The reduction in Adjusted EBITDA guidance is a negative signal, suggesting that ModivCare is facing more challenges than some of its competitors.
• Companies like LogistiCare (now part of Carelon) and Access2Care are also major players in the NEMT space, and their financial performance would be a relevant benchmark for comparison.
• The 10% growth target for 2025 is a positive sign, but it will be important to see if ModivCare can achieve this given the current challenges.

Stakeholder Impact

• Shareholders may react negatively to the reduced 2024 Adjusted EBITDA guidance.
• Employees may be concerned about the company's financial performance and potential cost-cutting measures.
• Customers may be affected by any changes in pricing or service delivery.
• Creditors may be concerned about the company's ability to meet its financial obligations.

Next Steps

• ModivCare will continue discussions with its bank group to seek near-term covenant relief.
• The company will focus on collecting outstanding receivables from its MCO and state payor customers.
• ModivCare will work towards aligning prepayment rates to stabilize the collection situation by 2025.

Key Dates

Keywords

ModivCare, NEMT, Adjusted EBITDA, Receivables, Medicaid, Healthcare Services, Financial Guidance, Covenant Relief, Capital Raise, Form S-3